Figure 4

Overview of the main proteins whose predicted differential activity levels are predicted to differentiate the effects of “emicizumab plus aPCC” vs. those of “emicizumab plus rFVIIa”. (a) Number of proteins whose functions are predicted to be perturbed by the combination of “emicizumab plus rFVIIa” vs. “emicizumab plus aPCC”. (b) Differential predicted protein activity of proteins that allow to differentiate the effects of “emicizumab plus aPCC” vs. those of “emicizumab plus rFVIIa”; Inhibited proteins indicate an inhibition in “emicizumab plus aPCC” respect “emicizumab plus rFVIIa”, Activated proteins indicate an activation in “emicizumab plus aPCC” respect “emicizumab plus rFVIIa”. aPCC activated prothrombin complex concentrate, FVIIa activated factor VII, GNAS adenylate cyclase-stimulating G alpha protein, ITGB3 integrin beta-3, KLK1 kallikrein, KNG1 kininogen, MoA mechanism of action, PIK3CA phosphatidylinositol 3-kinase catalytic, alpha, PIK3CD phosphatidylinositol 3-kinase catalytic, gamma, PIK3CG phosphatidylinositol 3-kinase catalytic, gamma, PIK3R5 phosphoinositide-3-kinase, regulatory subunit 5, PLCG1 phospholipase C, gamma 1, PRKACA cAMP-dependent protein kinase catalytic subunit alpha, rFVIIa recombinant activated factor VII.